Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis.

Chaker L, Baumgartner C, den Elzen WP, Collet TH, Ikram MA, Blum MR, Dehghan A, Drechsler C, Luben RN, Portegies ML, Iervasi G, Medici M, Stott DJ, Dullaart RP, Ford I, Bremner A, Newman AB, Wanner C, Sgarbi JA, Dörr M, Longstreth WT Jr, Psaty BM, Ferrucci L, Maciel RM, Westendorp RG, Jukema JW, Ceresini G, Imaizumi M, Hofman A, Bakker SJ, Franklyn JA, Khaw KT, Bauer DC, Walsh JP, Razvi S, Gussekloo J, Völzke H, Franco OH, Cappola AR, Rodondi N, Peeters RP; Thyroid Studies Collaboration.

J Clin Endocrinol Metab. 2016 Nov;101(11):4270-4282. Epub 2016 Sep 7.

PMID:
27603906
2.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

3.

Autoimmune thyroid disease: what secrets we still need to unravel?

Sgarbi JA.

Arch Endocrinol Metab. 2015 Apr;59(2):95-7. doi: 10.1590/2359-3997000000019. Epub 2015 Apr 1. No abstract available.

4.

Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts.

Åsvold BO, Vatten LJ, Bjøro T, Bauer DC, Bremner A, Cappola AR, Ceresini G, den Elzen WP, Ferrucci L, Franco OH, Franklyn JA, Gussekloo J, Iervasi G, Imaizumi M, Kearney PM, Khaw KT, Maciel RM, Newman AB, Peeters RP, Psaty BM, Razvi S, Sgarbi JA, Stott DJ, Trompet S, Vanderpump MP, Völzke H, Walsh JP, Westendorp RG, Rodondi N; Thyroid Studies Collaboration.

JAMA Intern Med. 2015 Jun;175(6):1037-47. doi: 10.1001/jamainternmed.2015.0930.

5.

Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis.

Chaker L, Baumgartner C, den Elzen WP, Ikram MA, Blum MR, Collet TH, Bakker SJ, Dehghan A, Drechsler C, Luben RN, Hofman A, Portegies ML, Medici M, Iervasi G, Stott DJ, Ford I, Bremner A, Wanner C, Ferrucci L, Newman AB, Dullaart RP, Sgarbi JA, Ceresini G, Maciel RM, Westendorp RG, Jukema JW, Imaizumi M, Franklyn JA, Bauer DC, Walsh JP, Razvi S, Khaw KT, Cappola AR, Völzke H, Franco OH, Gussekloo J, Rodondi N, Peeters RP; Thyroid Studies Collaboration.

J Clin Endocrinol Metab. 2015 Jun;100(6):2181-91. doi: 10.1210/jc.2015-1438. Epub 2015 Apr 9. Review.

6.

Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis.

Collet TH, Bauer DC, Cappola AR, Asvold BO, Weiler S, Vittinghoff E, Gussekloo J, Bremner A, den Elzen WP, Maciel RM, Vanderpump MP, Cornuz J, Dörr M, Wallaschofski H, Newman AB, Sgarbi JA, Razvi S, Völzke H, Walsh JP, Aujesky D, Rodondi N; Thyroid Studies Collaboration.

J Clin Endocrinol Metab. 2014 Sep;99(9):3353-62. doi: 10.1210/jc.2014-1250. Epub 2014 Jun 10.

7.

Clinical practice guidelines for the management of hypothyroidism.

Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Andrada NC, Bravo PP, Orlandi AM, Graf H; Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS).

Arq Bras Endocrinol Metabol. 2013 Jun;57(4):265-91. English, Portuguese.

8.

The Brazilian consensus for the clinical approach and treatment of subclinical hypothyroidism in adults: recommendations of the thyroid Department of the Brazilian Society of Endocrinology and Metabolism.

Sgarbi JA, Teixeira PF, Maciel LM, Mazeto GM, Vaisman M, Montenegro Junior RM, Ward LS; Brazilian Society of Endocrinology and Metabolism.

Arq Bras Endocrinol Metabol. 2013 Apr;57(3):166-83. English, Portuguese.

9.

Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.

Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N; Thyroid Studies Collaboration.

Arch Intern Med. 2012 May 28;172(10):799-809. doi: 10.1001/archinternmed.2012.402. Review.

10.

Parity is not related to autoimmune thyroid disease in a population-based study of Japanese-Brazilians.

Sgarbi JA, Kasamatsu TS, Matsumura LK, Maciel RM.

Thyroid. 2010 Oct;20(10):1151-6. doi: 10.1089/thy.2009.0424.

PMID:
20883173
11.

Subclinical hypothyroidism and the risk of coronary heart disease and mortality.

Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J; Thyroid Studies Collaboration.

JAMA. 2010 Sep 22;304(12):1365-74. doi: 10.1001/jama.2010.1361.

12.
13.

Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study.

Sgarbi JA, Matsumura LK, Kasamatsu TS, Ferreira SR, Maciel RM.

Eur J Endocrinol. 2010 Mar;162(3):569-77. doi: 10.1530/EJE-09-0845. Epub 2009 Dec 4.

14.

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators.

Int J Clin Pract. 2009 Sep;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.x. Epub 2009 Jul 15. Erratum in: Int J Clin Pract. 2010 Jan;64(2):277.

15.

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators.

Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x.

PMID:
19515181
16.

[Pathogenesis of autoimmune thyroid diseases].

Sgarbi JA, Maciel RM.

Arq Bras Endocrinol Metabol. 2009 Feb;53(1):5-14. Review. Portuguese.

17.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327
18.

[Subclinical thyroid disease: subclinical hypothyroidism and hyperthyroidism].

Romaldini JH, Sgarbi JA, Farah CS.

Arq Bras Endocrinol Metabol. 2004 Feb;48(1):147-58. Epub 2004 Jun 1. Review. Portuguese.

19.

The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities.

Sgarbi JA, Villaça FG, Garbeline B, Villar HE, Romaldini JH.

J Clin Endocrinol Metab. 2003 Apr;88(4):1672-7.

PMID:
12679455
20.

The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.

Bromberg N, Romaldini JH, Werner RS, Sgarbi JA, Werner MC.

J Endocrinol Invest. 1992 Mar;15(3):191-5.

PMID:
1624679

Supplemental Content

Loading ...
Support Center